Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
AssigneeAcceleron Pharma Inc.
InventorsJasbir Seehra, John Knopf, Robert S. Pearsall, Asya Grinberg, Ravindra Kumar
Life of this patent
Estimating the term…
Abstract
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
Claims25
A humanized or fully human antibody that binds to an ALK1 ligand and inhibits the binding of the ALK1 ligand to ALK1, wherein the ALK1 ligand is selected from the group consisting of BMP9 and BMP10.
A method of inhibiting angiogenesis in a mammal, the method comprising, administering to the mammal an effective amount of an agent selected from the group consisting of:
- an antagonist of BMP9, an antagonist of BMP10 and an antagonist of both BMP9 and BMP10.
8-9. (canceled)
11-12. (canceled)
(canceled)
A method for treating rheumatoid arthritis in a mammal, the method comprising, administering to a mammal that has rheumatoid arthritis an effective amount of an agent that binds to an ALK1 ligand and inhibits the binding of the ALK1 ligand to ALK1, wherein the ALK1 ligand is selected from the group consisting of GDF5, GDF6, GDF7, BMP9 and BMP10.
23-24. (canceled)
A method for treating a tumor in a mammal, the method comprising, administering to a mammal that has a tumor an effective amount of an agent that binds to an ALK1 ligand and inhibits the binding of the ALK1 ligand to ALK1, wherein the ALK1 ligand is selected from the group consisting of GDF5, GDF6, GDF7, BMP9 and BMP10.
26-33. (canceled)
An ophthalmic pharmaceutical formulation comprising an agent that binds to an ALK1 ligand and inhibits the binding of the ALK1 ligand to ALK1, wherein the ALK1 ligand is selected from the group consisting of GDF5, GDF6, GDF7, BMP9 and BMP10.
A method of treating an angiogenesis related disease of the eye comprising administering systemically or to said eye a pharmaceutical formulation comprising:
- an effective amount of an agent that binds to an ALK1 ligand and inhibits the binding of the ALK1 ligand to ALK1, wherein the ALK1 ligand is selected from the group consisting of GDF5, GDF6, GDF7, BMP9 and BMP10.
Dependencies are inferred from the claim text.